SCHOLAR ROCK HOLDING CORPORATION Operating Lease, Payments
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Operating Lease, Payments of $3.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION operating lease, payments for the quarter ending 2026-06-30 was $1.68M, a 17.95% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, payments for the quarter ending 2026-03-31 was $1.68M, a 17.89% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, payments for the quarter ending 2025-12-31 was $1.59M, a 22.53% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, payments for the quarter ending 2025-09-30 was $1.68M, a 17.62% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, payments for fiscal 2025 was $7.37M, a 8.48% decline from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, payments for fiscal 2024 was $8.05M, a 11.11% decline from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, payments for fiscal 2023 was $9.06M, a 1.37% decline from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION operating lease, payments for fiscal 2022 was $9.18M, a 3.41% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.37M 10-Q · filed 2026-08-06 | $4.96M derived: sum of 3 quarters · filed 2026-08-06 | $6.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.68M 10-Q · filed 2026-05-07 | $3.27M derived: sum of 2 quarters · filed 2026-05-07 | $4.95M derived: sum of 3 quarters · filed 2026-05-07 | $7.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.27M derived: sum of 2 quarters · filed 2026-03-03 | $5.32M derived: sum of 3 quarters · filed 2026-08-06 | $7.37M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.73M derived: sum of 2 quarters · filed 2026-08-06 | $5.78M 10-Q · filed 2025-11-14 | $7.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.10M 10-Q · filed 2026-08-06 | $6.15M derived: sum of 3 quarters · filed 2026-08-06 | $8.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.05M 10-Q · filed 2026-05-07 | $4.10M derived: sum of 2 quarters · filed 2026-05-07 | $6.14M derived: sum of 3 quarters · filed 2026-05-07 | $8.12M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.09M derived: sum of 2 quarters · filed 2026-03-03 | $6.07M derived: sum of 3 quarters · filed 2026-03-03 | $8.05M 10-K · filed 2026-03-03 |
| 2024-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $4.02M derived: sum of 2 quarters · filed 2025-11-14 | $6.00M 10-Q · filed 2025-11-14 | $7.98M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.96M 10-Q · filed 2025-08-06 | $5.94M derived: sum of 3 quarters · filed 2025-08-06 | $8.20M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.98M 10-Q · filed 2024-05-07 | $3.96M derived: sum of 2 quarters · filed 2024-05-07 | $6.21M derived: sum of 3 quarters · filed 2024-05-07 | $8.70M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $4.23M derived: sum of 2 quarters · filed 2024-03-19 | $6.72M derived: sum of 3 quarters · filed 2024-03-19 | $9.06M 10-K · filed 2024-03-19 |
| 2023-09-30 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $4.74M derived: sum of 2 quarters · filed 2023-11-07 | $7.08M 10-Q · filed 2023-11-07 | $9.42M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $4.82M 10-Q · filed 2023-08-09 | $7.16M derived: sum of 3 quarters · filed 2023-08-09 | $9.48M derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | $2.34M 10-Q · filed 2023-05-09 | $4.68M derived: sum of 2 quarters · filed 2023-05-09 | $7.00M derived: sum of 3 quarters · filed 2023-05-09 | $9.26M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $4.66M derived: sum of 2 quarters · filed 2023-03-07 | $6.92M derived: sum of 3 quarters · filed 2023-03-07 | $9.18M 10-K · filed 2023-03-07 |
| 2022-09-30 | $2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $4.58M derived: sum of 2 quarters · filed 2022-11-14 | $6.84M 10-Q · filed 2022-11-14 | $9.11M derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $4.53M 10-Q · filed 2022-08-08 | $6.79M derived: sum of 3 quarters · filed 2022-08-08 | $9.03M derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | $2.26M 10-Q · filed 2022-05-16 | $4.53M derived: sum of 2 quarters · filed 2022-05-16 | $6.76M derived: sum of 3 quarters · filed 2022-05-16 | $7.83M derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $4.50M derived: sum of 2 quarters · filed 2022-03-07 | $5.56M derived: sum of 3 quarters · filed 2022-03-07 | $8.88M 10-K · filed 2022-03-07 |
| 2021-09-30 | $2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $3.30M derived: sum of 2 quarters · filed 2021-11-09 | $6.62M 10-Q · filed 2021-11-09 | $7.67M derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $4.38M 10-Q · filed 2021-08-10 | $5.43M derived: sum of 3 quarters · filed 2021-08-10 | $5.78M derived: sum of 4 quarters · filed 2021-08-10 |
| 2021-03-31 | $3.32M 10-Q · filed 2021-05-13 | $4.37M derived: sum of 2 quarters · filed 2021-05-13 | $4.72M derived: sum of 3 quarters · filed 2021-05-13 | $5.08M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $1.41M derived: sum of 2 quarters · filed 2021-03-09 | $1.76M derived: sum of 3 quarters · filed 2021-03-09 | $2.11M 10-K · filed 2021-03-09 |
| 2020-09-30 | $353.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $706.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.06M 10-Q · filed 2020-11-09 | $1.41M derived: sum of 4 quarters · filed 2020-11-09 |
| 2020-06-30 | $353.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $706.00K 10-Q · filed 2020-08-07 | $1.06M derived: sum of 3 quarters · filed 2020-08-07 | $1.40M derived: sum of 4 quarters · filed 2020-08-07 |
| 2020-03-31 | $353.00K 10-Q · filed 2020-05-07 | $705.00K derived: sum of 2 quarters · filed 2020-05-07 | $1.05M derived: sum of 3 quarters · filed 2020-05-07 | $1.39M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $694.00K derived: sum of 2 quarters · filed 2020-03-12 | $1.04M derived: sum of 3 quarters · filed 2020-03-12 | $1.27M 10-K · filed 2020-03-12 |
| 2019-09-30 | $342.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $685.00K derived: sum of 2 quarters · filed 2019-11-12 | $914.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $343.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $572.00K 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $229.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |